All News

RheumNow Podcast square

Fallen Angels (1.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article
eyes

Best of 2024: Diagnosing Seronegative Sjogren's Disease

Jack Cush, MD

Sjögren disease (SjD) is highly prevalent, but diagnosis may be challenged if anti-SSA antibodies or a labial salivary gland biopsy are negative. A recent cohort analysis suggests a novel autoantibody profile has predictive value SSA negative SjD and also in those with a positive labial biopsy.

Read Article
eyes

Phase 2b Study of Ianalumab in Sjögren's

Jack Cush, MD

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

Read Article
Meeting audience conference

ACR 2024 - Day 1 Report

Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
QD Clinic - ANA Negative Lupus Pregnant ANA negative SLE (?) patients with Sjogrens and FM - what to do? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6… https://t.co/RyCdiadn4H https://t.co/EvWcQ6KIxQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled,… https://t.co/kkIOCUZRml https://t.co/nL47c5veCp
Dr. John Cush RheumNow ( View Tweet)
Phase 2b Study of Ianalumab in Sjögren's A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD). https://t.co/08W0N1f3ap https://t.co/lyZwGI56Qq

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR24: What I learned in Sjogren's, Takayasu's and CAR-T Dr. Janet Pope reviews abstract 2527 and abstract 1696. https://t.co/rrrGnOhfIV https://t.co/Ht1UTtYOLI

Links:

Dr. John Cush RheumNow ( View Tweet)
Differential diagnosis of ACA+ 1. SSc 2. Sjogren Syndrome 3. PBC 4. Overalp syndrome https://t.co/JmqDaaZerJ

Links:

Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
#Ianalumab 300 mg sc q monthly B cell depleted and changes BAFF signalling 👇⬇️IFN May be promising in #lupus #SLE +data in primary #Sjogrens ACR24 @RheumNow @ACRheum Abst#2425 Needs Phase3 ➡️I suspect safer than CAR T and Bispecific T cell engagers but ? ⬇️efficacy

Janet Pope Janetbirdope ( View Tweet)

#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease 👏Phase 2 +RCT ESSSDAI and ESPRI both improved 🤷‍♀️what it means to lower #antibodoes #Ro #La Excited for Phase 3 results #ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16

Links:

Janet Pope Janetbirdope ( View Tweet)
A#2291 ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens Symptomatology is complex in SjD and beyond traditional disease activity markers @RheumNow #ACR24 https://t.co/AhstAFjOVS

Links:

Eric Dein ericdeinmd ( View Tweet)
A#2530 ANA reactive CD4 cells: elevated B cell help activation in SjD Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc Leads to decrease activation of APCs, decrease CD4 T effector fxn @RheumNow #ACR24 https://t.co/4JnA3SpVM8

Links:

Eric Dein ericdeinmd ( View Tweet)
Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR

Links:

Richard Conway RichardPAConway ( View Tweet)
Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions. DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66

Links:

Eric Dein ericdeinmd ( View Tweet)
Now that nipocalimab is approved for Sjogren's Disease, what about vaccination response whilst on this FcRn inhibitor (inherently lowers IgG)? Actually, not bad: takes a little longer to get there, but reassuring! (always fun to get to know a new med) #ACR24 ABST1988 @RheumNow https://t.co/IYqIGo5xVP

Links:

David Liew drdavidliew ( View Tweet)
Salivary glands in #Sjogens #Disease Have persistent #IFN signature Abnormal morphology ⬇️ secretory ability In Differentiated salivary gland organoids DSGO May aid in drug screening Would drugs that ⬇️ #interferon help #Sjogren’s Abst#1406 @RheumNow @ACRheum #ACR24 https://t.co/dppp0tyFk5

Links:

Janet Pope Janetbirdope ( View Tweet)

FDA has given FDA Breakthrough Therapy designation to Nipocalimab for treatment of adults w/ moderate-to-severe Sjögren’s disease. NIPO is an Ab to neonatal Fc receptor (FcRn), & was tested and shown effective in Sjog in the Phase 2 DAHLIAS study - a plenary presentation at… https://t.co/aQDp7iPKXD https://t.co/hJ8fe6JwxC
Dr. John Cush RheumNow ( View Tweet)
Treatment alert for Sjogrens TWINSS study: Iscalimab CD40/CD40L monoclonal Ab: Improves disease activity Also helps fatigue and sicca, not pain Dazodalibep - CD40L antagonist also reduce symptoms/disease activity Year in Review #ACR24 Pillinger @RheumNow https://t.co/WjHuEpm9XW

Links:

Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×